Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  abiraterone acetate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 49 for your search:
Start Over
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Phase: Phase IV
Type: Health services research, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR105924, 212082-PCR-4020, NCT02364531
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR106841, ABI-C-14-JP-001-V03, NCT02405858
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Phase: Phase III, Phase II
Type: Diagnostic, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-003058-25, NCT01981707
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 22 and over
Sponsor: Other
Protocol IDs: ANDA208414, FWA00015357, IORG0007849, IRB00009424, IND78420, NPI1831468511, NPI1023387701, NCT02403505
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A031201, U10CA031946, NCI-2013-01737, NCT01949337
A Phase III of ADT +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UC-0160/1105, NCT01957436
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR105505, 56021927PCR3001, NCT02257736
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000614059, CRUK-CR9304-21, EUDRACT-2007-003240-30, CR9304-21, NCT00755885
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12-120, NCT01688492
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEP12-UC-0101/1104, NCT01780220
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13P.128, 2013-02, NCT01848067
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 7639, NCI-2011-03745, P30CA015704, NCT01503229
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 11-0709, NCI-2012-00116, NCT01543776
AMG 386 and Abiraterone for Advanced Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120079, 12-C-0079, NCT01553188
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01149, CDR0000730114, UCCRC-IL057, 12-0109, 9012, N01CM00038, N01CM00039, N01CM00071, P30CA014599, U01CA062491, U01CA070095, IL057, NCT01576172
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: MetAb-Pro, NCT01677897
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GU12-159, NCT01681433
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: Pro00044071, NCT01717053
Abiraterone Acetate Trial in African American Prostate Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 12-1727, NCT01735396
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IC 2012-04, NCT01771458
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0993, NCI-2013-00460, NCT01786265
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18 to 90
Sponsor: NCI, Other
Protocol IDs: 081214, Pro2013002775, P30CA072720, NCI-2013-02403, NCT01828476
Abiraterone Acetate in Molecular Apocrine Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CADUSEIME02, 2012-002525-29, UC-0140/1206, NCT01842321
Start Over